中国胰腺癌新辅助治疗指南(2020版)

2020-09-10 中华医学会外科学分会胰腺外科学组 中华外科杂志.2020,58(9):657-667.

为提高我国胰腺癌的总体治疗水平,中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会组织相关专家制定本指南。本指南基于GRADE系统,针对胰腺癌新辅助治疗的应用指征、方案选择、疗效评

中文标题:

中国胰腺癌新辅助治疗指南(2020版)

发布日期:

2020-09-10

简要介绍:

为提高我国胰腺癌的总体治疗水平,中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会组织相关专家制定本指南。本指南基于GRADE系统,针对胰腺癌新辅助治疗的应用指征、方案选择、疗效评估及其相关病理学诊断、手术策略等热点问题展开讨论,对现有临床研究的证据等级量化评估并提出推荐意见,以指导并促进胰腺癌新辅助治疗的临床实践。本指南强调多学科综合治疗协作组的重要地位,体现了胰腺癌治疗理念的转变。新辅助治疗能够有效延长部分胰腺癌患者的生存期,但仍需开展高质量临床研究,以进一步提升证据等级,完善临床实践方案,改善患者预后。

下载附件:

(因为版权问题,不支持下载)

评论区 (34)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1062506, encodeId=44071062506ce, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:38:58 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978099, encodeId=6ee39e80990c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bde05537364, createdName=ms4000001479889685, createdTime=Wed Jun 30 06:49:08 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961045, encodeId=cfdd961045ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:45 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961044, encodeId=b5bc9610448f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:37 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961042, encodeId=c65c961042b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:53:14 CST 2021, time=2021-04-27, status=1, ipAttribution=)]
    2021-10-21 ms8000001549818402

    #学习#非常有用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1062506, encodeId=44071062506ce, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:38:58 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978099, encodeId=6ee39e80990c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bde05537364, createdName=ms4000001479889685, createdTime=Wed Jun 30 06:49:08 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961045, encodeId=cfdd961045ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:45 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961044, encodeId=b5bc9610448f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:37 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961042, encodeId=c65c961042b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:53:14 CST 2021, time=2021-04-27, status=1, ipAttribution=)]
    2021-06-30 ms4000001479889685

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1062506, encodeId=44071062506ce, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:38:58 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978099, encodeId=6ee39e80990c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bde05537364, createdName=ms4000001479889685, createdTime=Wed Jun 30 06:49:08 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961045, encodeId=cfdd961045ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:45 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961044, encodeId=b5bc9610448f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:37 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961042, encodeId=c65c961042b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:53:14 CST 2021, time=2021-04-27, status=1, ipAttribution=)]
    2021-04-27 ms4000000509959811

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1062506, encodeId=44071062506ce, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:38:58 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978099, encodeId=6ee39e80990c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bde05537364, createdName=ms4000001479889685, createdTime=Wed Jun 30 06:49:08 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961045, encodeId=cfdd961045ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:45 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961044, encodeId=b5bc9610448f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:37 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961042, encodeId=c65c961042b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:53:14 CST 2021, time=2021-04-27, status=1, ipAttribution=)]
    2021-04-27 ms4000000509959811

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1062506, encodeId=44071062506ce, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:38:58 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978099, encodeId=6ee39e80990c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bde05537364, createdName=ms4000001479889685, createdTime=Wed Jun 30 06:49:08 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961045, encodeId=cfdd961045ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:45 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961044, encodeId=b5bc9610448f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:57:37 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961042, encodeId=c65c961042b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67645487123, createdName=ms4000000509959811, createdTime=Tue Apr 27 20:53:14 CST 2021, time=2021-04-27, status=1, ipAttribution=)]
    2021-04-27 ms4000000509959811

    0

拓展阅读

2010ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

胰腺癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

2012 胰腺癌经动脉灌注化疗指南(草案)

中华医学会放射学分会介入学组 · 2012-05-30

2012 ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2013 胰腺癌多学科综合治疗协作组专家共识

中华医学会肿瘤学分会 · 2013-05-01